TY - CHAP M1 - Book, Section TI - Metastatic Breast Cancer A1 - Isakoff, Steven J. A2 - Chabner, Bruce A. A2 - Longo, Dan L. Y1 - 2016 N1 - T2 - Harrison's Manual of Oncology, 2e AB - Since 1990, the annual rate of breast cancer death has been decreasing by approximately 2.2% per year (1). Historically, median survival of patients with metastatic breast cancer (MBC) was estimated to be 18–30 months. Many experts agree that median survival has improved in recent years beyond 30 months, although survival varies significantly by breast cancer subtype. A number of newer active agents have recently been added to the armamentarium against breast cancer, including third-generation aromatase inhibitors, novel antimicrotubule chemotherapy agents, and biologic agents such as lapatinib, pertuzumab, and everolimus. Despite these advances, breast cancer remains the second leading cause of cancer death in women in the United States, with 39,620 women estimated to die of breast cancer in 2013 (1). SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1127649621 ER -